Case Studies
Clovis Oncology
Clovis Oncology has chosen Quotient’s drug product optimization approach for rociletinib, a promising oral candidate drug for the treatment of EGFR-resistant non-small cell lung cancer.
Advancing the Pharmaceutical Development of Orphan Drugs for Rare Diseases
Case Studies
Clovis Oncology has chosen Quotient’s drug product optimization approach for rociletinib, a promising oral candidate drug for the treatment of EGFR-resistant non-small cell lung cancer.
Ask us a question